CKD Bio Corp.

KOSE:A063160 Voorraadrapport

Marktkapitalisatie: ₩159.6b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

CKD Bio Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Hui Kang

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOno data
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Recent updates

What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition

Feb 28
What You Need To Know About CKD Bio Corp.'s (KRX:063160) Investor Composition

Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?

Feb 01
Is CKD Bio's (KRX:063160) 203% Share Price Increase Well Justified?

CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt

Jan 11
CKD Bio (KRX:063160) Takes On Some Risk With Its Use Of Debt

What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us

Dec 21
What CKD Bio Corp.'s (KRX:063160) ROE Can Tell Us

Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential

Nov 30
Here's Why We Don't Think CKD Bio's (KRX:063160) Statutory Earnings Reflect Its Underlying Earnings Potential

CEO

Hui Kang

no data

Tenure

Mr. Hui Yil Kang serves as a Co-Chief Executive Officer, Vice President, and Director of Ckd Bio Corporation.